Association of Inpatient vs. Outpatient Onset of ST-Elevation Myocardial Infarction With Treatment and Clinical Outcomes

20.11.20141695
What are the incidence and variables associated with treatment and outcomes of patients with inpatient-onset ST-segment elevation myocardial infarction (STEMI)?

What is the Long-Term Cause of Death in STEMI Patients Treated With Primary PCI?

19.11.20141885
The risk of cardiac mortality declines to less than 1.5 percent per year following survival after a ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI), and noncardiac causes are responsible for the majority of later deaths in these patients, according to a study published Nov. 10 in the Journal of the American College of Cardiology.

The QT Interval Is Associated With Incident Cardiovascular Events: The MESA Study

18.11.20142133
Study Question: Is the baseline QT interval predictive of negative cardiovascular outcomes?

Study Examines Follow-Ups in Adolescents With Family History of Brugada Syndrome

17.11.20141575
В соответствии с исследованием, опубликованным 16 ноября в журнале Американской медицинской ассоциации, у пациентов с семейным анамнезом синдрома Бругада и отрицательным результатом теста, проведенным в детстве, синдром может развиться в последующей жизни в результате действия гормональных, вегетативных или генетических факторов.

Clinical trial will explore bone marrow-derived cell therapy for HF

14.11.20141627
The FDA has accepted an application to begin a phase 3 clinical trial of bone marrow-derived cell therapy for patients with HF, according to a press release from BioCardia Inc.

Long-term weight loss, CV health similar among four popular diets

13.11.20141732
Patients achieved similar but modest weight loss with the Atkins, South Beach, Weight Watchers and Zone diets, according to a systematic review published in Cardiovascular Quality and Outcomes.

CardioBuzz: Update on Antidotes for New Oral Anticoagulants

11.11.20141880
The New England Journal of Medicine reported last week a phase I study of a new drug (PER977, Aripazine) that may be effective as an antidote for several of the new oral anticoagulants, as well as some of the established anticoagulants.
Данный сайт и вся информация на нём предназначена для медицинских работников. Продолжая просмотр, вы соглашаетесь и подтверждаете, что являетесь медицинским работником.